Correction to: Effects of short-term tofogliflozin treatment on the insulin secretory capacity of people with type 2 diabetes: A randomized controlled trial, the TOP - ELM study (Journal of Diabetes Investigation, (2026), 17, 4, (627-635), 10.1111/jdi.70245)

Miyamoto M, Miya A, Nakamura A, Takahashi Y, Yamauchi Y, Yanagiya S, Takase T, Ono M, Takahashi K, Okada K, Kameda H, Cho KY, Atsumi T, TOP-ELM Study Group. Effects of short-term tofogliflozin treatment on the insulin secretory capacity of people with type 2 diabetes: A randomized controlled trial, the TOP-ELM study. J Diabetes Investig 2026; 17: 627-635. https://doi.org/10.1111/jdi.70245. In Table 4, the reported values for the change in the proinsulin/C-peptide (PI/CPR) ratio were incorrect. The corrected values are shown below. This correction does not affect the statistical significance of the results or the conclusions of the article. 4 Table Comparisons between the metformin and tofogliflozin groups with respect to glucose metabolism parameters at Week 4. (Table presented.) Values are mean or median (95% confidence interval). Within-group P values were obtained using the paired t-test or the Wilcoxon signed rank test. The metformin and tofogliflozin groups were compared after 4 weeks using the unpaired t-test or the Mann–Whitney U-test. Abbreviations: AUCglu, area under the curve for glucose; AUCins, area under the curve for insulin; CPR, C-peptide; DI, disposition index; HOMA-IR, homeostasis model assessment–insulin resistance; II, insulinogenic index; ISSI-2, insulin secretion sensitivity index; MI, Matsuda index. We apologize for this error.